Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
₹9 Cr
P/E Ratio
--
P/B Ratio
4.27
Industry P/E
32.09
Debt to Equity
0.64
ROE
-117.48 %
ROCE
-60.11 %
Div. Yield
0 %
Book Value
2.63
EPS
-5.96
CFO
₹27.61 Cr
EBITDA
₹30.45 Cr
Net Profit
₹-3.96 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ortin Laboratories
| -36.59 | -11.85 | -32.83 | -42.11 | -26.73 | -8.26 | -- |
|
BSE Healthcare
| -7.68 | 6.11 | -2.04 | 19.11 | 18.77 | 22.70 | 8.84 |
|
BSE Small Cap
| -12.49 | 9.35 | -8.34 | 5.55 | 17.55 | 35.38 | 15.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Ortin Laboratories
| -21.81 | -2.74 | -28.68 | -46.09 | 200.51 | -35.08 | -49.43 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 733.60 | 6,652.58 | 26.68 | 13.8 | |
| 2,322.20 | 9,511.53 | 78.36 | 12.96 | |
| 431.60 | 5,319.81 | 71.34 | 6.24 | |
| 913.20 | 5,216.91 | 40.95 | 14.76 |
No Review & Analysis are available.
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. It operates through Manufacture and Trading segments. The company offers various pharmaceutical formulations of tablets, capsules,... syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India. Read more
Incorporated
1986
Chairman
--
Managing Director
S Murali Krishna Murthy
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Ortin Laboratories Ltd stood at ₹ 4 Cr as on 31-Dec-24
The share price of Ortin Laboratories Ltd is ₹11.23 (NSE) and ₹11.00 (BSE) as of 17-Apr-2025 IST. Ortin Laboratories Ltd has given a return of -26.73% in the last 3 years.
Ortin Laboratories Ltd has a market capitalisation of ₹ 9 Cr as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Ortin Laboratories Ltd is 4.27 times as on 17-Apr-2025, a 15% premium to its peers’ median range of 3.70 times.
Since, TTM earnings of Ortin Laboratories Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ortin Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Ortin Laboratories Ltd.
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. It operates through Manufacture and Trading segments. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
There is no promoters in Ortin Laboratories Ltd.
There is no promoter pledging in Ortin Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,512
|
|
|
6,653
|
|
|
5,320
|
|
|
5,217
|
| Ortin Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-191.25
|
|
Operating margin(%)
|
-625.37
|
|
Net Margin(%)
|
-795.55
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Ortin Laboratories Ltd was ₹-5 Cr.
₹0.05
(
